| Deal value | $2.4B |
|---|---|
| Share of market cap | 3.7% |
| Share of annual revenue | 0.7% |
Key highlights
- Enterprise value of $2.4 billion includes $2.3 billion at closing and $100 million in contingent value rights
- Acquisition adds more than 350 oncology providers across 21 states to Cencora’s MSO platform
- Deal is expected to be accretive to Cencora’s adjusted diluted EPS in the second year post-closing
- Cencora expects a cash outlay of $1.7 billion assuming a 25% equity rollover by certain stockholders
- Transaction has been approved by AON’s Board of Directors following a special committee recommendation
What Is the Deal?
Cencora, Inc. has entered into a definitive merger agreement to acquire American Oncology Network (AON) for a total enterprise value of $2.4 billion. The consideration includes an upfront payment of $2.3 billion and additional contingent value rights (CVRs) of up to $100 million, payable upon the satisfaction of specific conditions. Cencora, which already holds a 4% equity interest in the target, will acquire all remaining shares. The deal structure allows for an equity rollover of up to 25% by existing AON stockholders, which would result in Cencora paying approximately $1.7 billion for a 75% stake at closing. The transaction is subject to regulatory approvals and AON stockholder consent.
Strategic Rationale
The acquisition is designed to expand Cencora’s physician-led oncology management services organization (MSO) by adding a footprint in 12 additional states. By bringing AON’s network of over 350 providers under its umbrella, Cencora aims to strengthen community-based cancer care and improve patient access to innovative therapies. The integration of AON is expected to enhance practice support capabilities and technological infrastructure for independent oncology practices. This alignment leverages Cencora's global pharmaceutical supply chain to support AON’s mission of delivering high-quality care in local settings. Clinical autonomy will remain with AON’s physicians following the completion of the merger.
Financial Context
This $2.4 billion transaction follows a period of aggressive expansion for Cencora in the specialty healthcare sector, including the $5.0 billion majority interest acquisition of OneOncology and the $4.6 billion purchase of Retina Consultants of America. Cencora recently updated its fiscal 2026 financial expectations, guiding for adjusted diluted earnings per share of at least $17.90. The company’s market capitalization stands at approximately $65.5 billion, and it reported annual revenue of $321.3 billion. This acquisition is projected to become accretive to adjusted diluted EPS in the second year after the transaction closes, reinforcing Cencora’s strategy of pivoting toward high-margin specialty services.
Up 4.0% since our story on 21 Oct: $343.27 when we broke it → $356.94 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $340.00 |
|---|---|
| 20 Oct | $343.27 |
| 21 Oct | $340.43 |
| 22 Oct | $338.48 |
| 23 Oct | $331.00 |
| 26 Oct | $330.00 |
| 27 Oct | $325.37 |
| 28 Oct | $324.35 |
| 29 Oct | $330.53 |
| 30 Oct | $330.84 |
| 2 Nov | $337.84 |
| 3 Nov | $340.50 |
| 4 Nov | $354.00 |
| 5 Nov | $339.68 |
| 6 Nov | $333.56 |
| 9 Nov | $345.76 |
| 10 Nov | $348.71 |
| 11 Nov | $349.88 |
| 12 Nov | $349.38 |
| 13 Nov | $359.03 |
| 16 Nov | $356.94 |
Industry Landscape
- Consolidation in community oncology continues as providers seek scale to manage rising operational costs
- The acquisition follows Cencora's $1.1 billion purchase of EyeSouth Partners' retina business in March 2026
- Specialty healthcare services are becoming a primary growth engine for major medical distributors
- Regulatory focus on vertical integration in the pharmacy and provider sectors remains a key variable for deal completion
- Market sentiment for Cencora is currently high, evidenced by an RSI of 70.8 and a 11.7% quarterly price increase
| Date | Announcement | Amount |
|---|---|---|
| 23 Mar 2026 | Acquisition of EyeSouth Partners' retina businessSource: healthcaredive.com | $1.10 Billion |
| 18 Feb 2026 | Merger and divestiture of MWI Animal Health with CovetrusSource: investor.amerisourcebergen.com | $3.50 Billion |
| 15 Dec 2025 | Acquisition of majority interest in OneOncologySource: fiercehealthcare.com | $5.00 Billion |
| 13 Oct 2025 | Acquisition of NextPharma Logistics GmbHSource: nextpharma.com | – |
| 06 Nov 2024 | Acquisition of Retina Consultants of AmericaSource: SEC filing | $4.60 Billion |
Management commentary
“The acquisition of AON will expand our physician-led oncology MSO and support of care in communities across the country.”
“This is the next chapter of the same mission: high-quality, accessible cancer care delivered close to home, led by physicians who know their patients best.”
| Share price | $343.27 |
|---|---|
| Market cap | $65.5B |
| Revenue (annual) | $321.3B |
| P/E (TTM) | 25.5× |
| 1-month price change | +11.17% |
| Sector | HealthcareMedical Distribution |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Cencora, Inc. announcing a definitive agreement to acquire American Oncology Network for $2.4 billion.
Track Cencora, Inc. live
Get the next Cencora, Inc. SEC filing seconds after it lands.



